Difference between revisions of "Letrozole (Femara)"
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020726s014lbl.pdf Letrozole (Femara) package insert]</ref><r...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020726s014lbl.pdf Letrozole (Femara) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/letrozole.pdf Letrozole (Femara) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues. Letrozole competitively binds to and inhibits the aromatase by binding to the heme of the enzyme's cytochrome P450.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020726s014lbl.pdf Letrozole (Femara) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/letrozole.pdf Letrozole (Femara) package insert (locally hosted backup)]</ref><ref>[http://www.femara.com Femara manufacturer's website]</ref> |
| − | <br>Route: | + | <br>Route: PO |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
Revision as of 17:32, 22 February 2012
General information
Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues. Letrozole competitively binds to and inhibits the aromatase by binding to the heme of the enzyme's cytochrome P450.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Letrozole (Femara) patient drug information (Chemocare)[4]
- Letrozole (Femara) patient drug information (UpToDate)[5]